Alvotech (ALVOW) stock analysis

From the 20-F filed 2026-03-31

How it makes money

Partners pay it milestones and royalties because it licenses the intellectual property for biosimilar medicines.

It develops biosimilars, which are biological medicines made from living cells that mimic expensive reference products after patents expire. It provides a cost-effective alternative to these biologics.

It does not sell these medicines directly to patients or hospitals. Instead, it licenses the technology to pharmaceutical partners who manage the commercialization in exchange for development payments and royalties on sales.

What protects it: the moat

It uses a vertically integrated platform to manage research, development, and manufacturing in-house.

Management claims that combining these functions within one organization allows it to be faster and cheaper than competitors. It relies on a purpose-built platform and a leadership team experienced in bringing biologics to market to maintain this advantage.

What growth costs

It invested over $2 billion in its platform and spent $64.5 million on capital expenditures in 2025.

The company requires heavy upfront investment to build and maintain the infrastructure needed for large-scale biologics production. Recent spending has focused on property, plant and equipment, as well as lab and computer equipment in Iceland.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.